But its experimental, and there are currently no robust clinical trials supporting its safety or efficacy in this context
Patients with certain genetic combinations may benefit from consistent weekly timing and stable doses, while others show greater flexibility in their response
So naturally, you add another leg day
[PubMed] [CrossRef] [Google Scholar] Kuu NK, Var A
The risk is not only the sequence Even where a molecule is biologically plausible, the product introduces a second layer of risk such as sterility and endotoxin contamination, incorrect peptide identity or concentration, degradation during storage, aggregation and immunogenicity, synthesis-related impurities, injection-site infection or granuloma, unpredictable systemic exposure and an absence of long-term carcinogenicity and reproductive data